Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 05, 2021

BUY
$16.3 - $21.14 $23,390 - $30,335
1,435 New
1,435 $30,000
Q2 2019

Aug 09, 2019

SELL
$18.93 - $24.75 $47,930 - $62,667
-2,532 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$19.6 - $24.76 $49,627 - $62,692
2,532 New
2,532 $60,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Mufg Americas Holdings Corp Portfolio

Follow Mufg Americas Holdings Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mufg Americas Holdings Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mufg Americas Holdings Corp with notifications on news.